Dr.Reddys Laboratories traded at 4,385.00 this Friday July 1st, decreasing 8.80 or 0.20 percent since the previous trading session. Looking back, over the last four weeks, Dr.Reddys Laboratories lost 1.20 percent. Over the last 12 months, its price fell by 21.36 percent. Looking ahead, we forecast Dr.Reddys Laboratories to be priced at 4,185.44 by the end of this quarter and at 3,832.95 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
4,385.00
Daily Change
-0.20%
Yearly
-21.36%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Aspen Pharmacare 14,052.00 148.00 1.06% -13.14%
Bharat Petroleum 312.35 3.95 1.28% -32.50%
Cipla 949.50 32.30 3.52% -3.03%
Dr.Reddys Laboratories 4,385.00 -8.80 -0.20% -21.36%
Reliance Infra 2,434.50 -161.15 -6.21% 14.35%
Sun Pharmaceuticals 830.50 -0.10 -0.01% 21.91%
UPL 640.00 7.60 1.20% -19.93%

Indexes Price Day Year
SENSEX 52908 -111.01 -0.21% 0.81%
NIFTY 50 15752 -28.20 -0.18% 0.19%

Dr.Reddys Laboratories
Dr. Reddy's Laboratories Limited is a pharmaceutical company that is engaged in providing medicines. The Company operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment includes manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). PSAI segment includes the Company's business of manufacturing and marketing active pharmaceutical ingredients and intermediates (API) or bulk drugs. Proprietary Products segment focuses on the research, development and manufacture of differentiated formulations and new chemical entities. These products fall within the dermatology and neurology therapeutic areas, and are marketed and sold through its subsidiary, Promius Pharma, LLC.